Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation (CERS) is a pioneering biomedical products company dedicated to enhancing blood safety worldwide. The company’s flagship technology, the INTERCEPT Blood System, aims to mitigate the risk of transfusion-transmitted diseases by inactivating a broad spectrum of pathogens, including viruses, bacteria, and parasites present in donated blood. Utilizing a unique nucleic acid targeting mechanism, the INTERCEPT system offers protection against established threats like Hepatitis B and C, HIV, West Nile Virus, and bacteria, while also being designed to inactivate emerging pathogens such as Influenza, Malaria, and Dengue.
Cerus Corporation markets and sells the INTERCEPT Blood System for both platelets and plasma in various regions including Europe, Russia, the Middle East, and selected countries globally. The INTERCEPT Red Blood Cell system is currently in clinical development, highlighting the company’s ongoing efforts to broaden its product offerings and enhance blood safety further.
Recent achievements for Cerus include expanding market reach, securing regulatory approvals, and forging key partnerships to strengthen its global presence. Financially, Cerus remains focused on sustaining growth through innovation and strategic collaborations.
By prioritizing safety and efficacy, Cerus Corporation plays a critical role in the field of blood transfusion safety, making significant strides in protecting public health on a global scale.
Cerus Corporation (NASDAQ: CERS) will release its third quarter 2021 financial results on November 2, 2021, after market close. A conference call and webcast are scheduled for 4:30 PM ET on the same day, where management will discuss the financial results and provide a business overview. The INTERCEPT Blood System, the company's flagship product, remains the only pathogen reduction system with CE mark and FDA approval for platelets and plasma. A replay of the call will be available post-event until November 16, 2021.
Today, the FDA's final guidance on bacterial risk control for platelet collection and transfusion takes effect, promoting the INTERCEPT Blood System for platelets by Cerus (CERS) as a compliant pathogen reduction solution. This system not only addresses bacterial contamination—recognized as a major risk in the U.S.—but also inactivates a range of viruses and parasites. The guidance aims to enhance platelet safety and availability for transfusions across the U.S., marking a significant milestone in transfusion medicine, as INTERCEPT is currently the only FDA-approved measure for compliance.
Cerus Corporation (NASDAQ: CERS) will participate in the Society for the Advancement of Blood Management Annual Meeting from September 22-25, 2021. On September 23, Cerus will host a workshop discussing the clinical need for the INTERCEPT Fibrinogen Complex, featuring presentations from hospital customers. The INTERCEPT Blood System for Cryoprecipitation is FDA approved since November 2020, aimed at improving treatment of massive hemorrhage. Additionally, CMS has granted a New Technology Add-On Payment for the INTERCEPT Fibrinogen Complex.
Cerus Corporation (Nasdaq: CERS) announces participation in the 2021 Cantor Global Virtual Healthcare Conference on September 29, 2021, at 11:20 a.m. ET. CEO William 'Obi' Greenman and CFO Kevin D. Green will represent the company. A live webcast will be accessible on Cerus’ Investor Relations page, with a replay available for two weeks post-event. Cerus is committed to protecting the global blood supply, offering the INTERCEPT Blood System, which has CE mark and FDA approval for pathogen reduction in platelets and plasma. For further details, visit Cerus Investor Relations.
Cerus Corporation (Nasdaq: CERS) has received permanent HCPCS Level II codes from CMS for its INTERCEPT Fibrinogen Complex (IFC) and Pathogen Reduced Plasma, effective October 1, 2021. These codes will aid hospitals in billing for these innovative products, enhancing access to transfusion medicine. Earlier, Cerus announced a new technology add-on payment for IFC within the Medicare Hospital Inpatient Prospective Payment System. The INTERCEPT Blood System, which also includes IFC, is designed for treating massive hemorrhage and has FDA Breakthrough Device designation.
Cerus Corporation (Nasdaq: CERS) has appointed Ann Lucena, CEO of San Ramon Regional Medical Center, to its Board of Directors. With a strong background in healthcare management, Lucena's experience is expected to add valuable insights from the provider community as Cerus aims to expand its blood safety product portfolio. Daniel Swisher, Chair of the Board, expressed enthusiasm for her addition, highlighting the ongoing paradigm shift in transfusion medicine and the importance of blood safety. Lucena's prior roles include Chief of Staff at Tenet Healthcare and healthcare consulting.
Cerus Corporation (Nasdaq: CERS) reported a strong second quarter of 2021, achieving total revenue of $37.8 million, a 41% year-over-year increase. Product revenue rose to $31.5 million, up 46% from 2020, driven by demand for INTERCEPT platelet products. The company has raised its annual product revenue guidance to $118-$122 million, marking a projected 28%-33% growth over 2020. Despite a net loss of $15.4 million for the quarter, the firm maintains healthy cash reserves of $123 million as of June 30, 2021.
Cerus Corporation (Nasdaq: CERS) announced that CMS has granted a new technology add-on payment (NTAP) for INTERCEPT Fibrinogen Complex under the Medicare Hospital Inpatient Prospective Payment System (IPPS). The NTAP, applicable for patients with massive bleeding due to fibrinogen deficiency, allows additional payment of up to $2,535 per patient when costs exceed the MS-DRG payment. This decision supports improved access to this innovative blood product, enhancing care in urgent situations. The INTERCEPT Blood System for Cryoprecipitation received FDA Breakthrough Device designation and was approved in November 2020.
Cerus Corporation (Nasdaq: CERS) is set to release its second quarter 2021 financial results on August 3, 2021, after market close. A conference call and webcast will follow at 4:30 PM ET, where management will discuss the financial outcomes and provide a business outlook. Investors can access the call via the Cerus Investor Relations website or through dedicated phone lines for U.S. and international participants. The replay will be available until August 17, 2021. Cerus is focused on enhancing blood safety through its INTERCEPT Blood System, with products approved in multiple regions.
FAQ
What is the current stock price of Cerus (CERS)?
What is the market cap of Cerus (CERS)?
What is Cerus Corporation's main focus?
What pathogens does the INTERCEPT Blood System target?
Where is the INTERCEPT Blood System marketed?
What products does Cerus Corporation offer?
What are some recent achievements of Cerus Corporation?
How does the INTERCEPT Blood System work?
What financial strategies does Cerus Corporation employ?
Is Cerus Corporation involved in research for emerging pathogens?
What regions are key markets for Cerus Corporation?
What segment does Cerus Corporation operate in?
